作者: 愛(ài)了嗎 時(shí)間: 2025-3-21 21:00 作者: engrossed 時(shí)間: 2025-3-22 00:57 作者: palliative-care 時(shí)間: 2025-3-22 04:47 作者: Synthesize 時(shí)間: 2025-3-22 09:44
Processing of Antigens by Dendritic Cells: Nature’s Adjuvants of these specialized antigen-presenting cells. The dendritic cells are then used in studies of mechanism of action, e.g., antigen uptake and processing. The findings also are being exploited in clinical studies where antigen-pulsed dendritic cells are being administered to initiate immunity in hum作者: 形容詞詞尾 時(shí)間: 2025-3-22 16:23 作者: 形容詞詞尾 時(shí)間: 2025-3-22 19:50 作者: WAG 時(shí)間: 2025-3-22 22:40
Isolation and Characterization of CD34-Low/Negative Mouse Hematopoietic Stem Cellsetic stem cells with long-term marrow repopulating ability whereas CD34. c-Kit. Sca-1. Lin. (CD34.KSL) cells are progenitors with short-term reconstitution capacity. To characterize these two populations of cells further, relative expression of various genes was examined by RT-PCR. In CD34.KSL cells作者: pacifist 時(shí)間: 2025-3-23 03:43 作者: Spartan 時(shí)間: 2025-3-23 06:39 作者: 流動(dòng)性 時(shí)間: 2025-3-23 13:32 作者: endarterectomy 時(shí)間: 2025-3-23 17:03
A Novel Acute Promyelocytic Leukemia Model: From Cell to Murine System patients achieve complete remission by the treatment of all-. RA; however, clinical remissions are usually of brief duration, and these patients often develop RA-resistant disease. The mechanisms of RA resistance in APL cells are poorly understood, and most clinical approaches have not been success作者: 稱贊 時(shí)間: 2025-3-23 18:59
Phase 1 Trial of Retroviral-Mediated Transfer of the Human MDR-1 in Patients Undergoing High-Dose Ch-sensitive drugs such as the vinca alkaloids, anthracyclines, podophyllotoxins, and taxanes. In this report of a phase 1 clinical study performed at the Columbia-Presbyterian Medical Center, we demonstrate the safety and efficacy of transfer of the human multiple drug resistance (MDR) gene into hema作者: intimate 時(shí)間: 2025-3-24 01:44
Basic Studies Toward Hematopoietic Stem Cell Gene Therapyare an ideal target for gene therapy. Retroviral vectors are predominantly used for transduction of HSCs, but the gene transfer efficiency is extremely low. Several efforts have been made at achieving clinically relevant gene transfer efficiencies. First, new cytokines such as Flt-3 ligand and throm作者: 不可救藥 時(shí)間: 2025-3-24 03:30
Ex Vivo Expansion of Hematopoietic Cells neutropenia following transplantation. To date, no clinical studies using ex vivo expanded cells have demonstrated any decrease in the time to neutrophil or platelet recovery, although a number of clinical studies have been performed using a variety of growth factor cocktails and culture conditions作者: Resistance 時(shí)間: 2025-3-24 10:15 作者: 充氣球 時(shí)間: 2025-3-24 13:02 作者: Ambiguous 時(shí)間: 2025-3-24 17:28 作者: Traumatic-Grief 時(shí)間: 2025-3-24 22:44 作者: 破譯 時(shí)間: 2025-3-25 01:38 作者: Liability 時(shí)間: 2025-3-25 05:27
978-4-431-68508-1Springer-Verlag Tokyo 2000作者: 遷移 時(shí)間: 2025-3-25 08:22 作者: 難管 時(shí)間: 2025-3-25 12:24
On a proof by Arbib, Kfoury, and Moll,ing tumor epitopes of human squamous cell carcinomas (SCCs) recognized by HLA-A2601-restricted CTLs. This gene showed no similarity to known sequences, and encoded two proteins, 125kDa of the SART1. nuclear protein and 43kDa of the SART1. cytosol protein. The SART1. protein with leucine-zipper motif作者: 音樂(lè)會(huì) 時(shí)間: 2025-3-25 15:48
Lecture Notes in Computer Sciencey has been investigating the use of adoptive immunotherapy with antigen-specific T-cell clones to prevent cytomegalovirus (CMV) infection in allogeneic bone marrow transplant (BMT) recipients; augment immune responses to human immunodeficiency virus (HIV) in HIV-seropositive individuals; and to indu作者: Interregnum 時(shí)間: 2025-3-25 22:45 作者: manifestation 時(shí)間: 2025-3-26 03:00 作者: Simulate 時(shí)間: 2025-3-26 04:51
,Proving theorems with Euclid’s algorithm,n the understanding of mechanisms of immune activation and immune escape during an antimelanoma-specific immune response has resulted in new concepts for immunotherapeutic intervention in this disease. In a clinical pilot trial, 30 metastatic melanoma patients were vaccinated with peptide- and/or tu作者: 防水 時(shí)間: 2025-3-26 10:17
On a proof by Arbib, Kfoury, and Moll, methods, we have identified melanoma antigens recognized by autologous T cells. These antigens are classified as (1) tissue- (melanocyte-) specific melanosomal proteins, (2) cancer-testis antigens (proteins expressed in normal testis and various cancers, and (3) tumor-specific peptides derived from作者: Addictive 時(shí)間: 2025-3-26 15:39 作者: Misnomer 時(shí)間: 2025-3-26 17:59 作者: echnic 時(shí)間: 2025-3-26 21:59 作者: 山羊 時(shí)間: 2025-3-27 04:06
Not about open and closed sets, more than 80% of myeloid leukemias have been attributed to, or associated with, one or more specific molecular lesions. In the vast majority of cases these molecular events are chromosomal translocations that rearrange the regulatory and coding regions of a variety of genes which encode transcripti作者: engender 時(shí)間: 2025-3-27 05:43
On the Shape of Mathematical Arguments patients achieve complete remission by the treatment of all-. RA; however, clinical remissions are usually of brief duration, and these patients often develop RA-resistant disease. The mechanisms of RA resistance in APL cells are poorly understood, and most clinical approaches have not been success作者: 不再流行 時(shí)間: 2025-3-27 10:56
A problem on bichrome 6-graphs,-sensitive drugs such as the vinca alkaloids, anthracyclines, podophyllotoxins, and taxanes. In this report of a phase 1 clinical study performed at the Columbia-Presbyterian Medical Center, we demonstrate the safety and efficacy of transfer of the human multiple drug resistance (MDR) gene into hema作者: 慢慢啃 時(shí)間: 2025-3-27 13:45 作者: 恭維 時(shí)間: 2025-3-27 20:15
https://doi.org/10.1007/BFb0020908 neutropenia following transplantation. To date, no clinical studies using ex vivo expanded cells have demonstrated any decrease in the time to neutrophil or platelet recovery, although a number of clinical studies have been performed using a variety of growth factor cocktails and culture conditions作者: 安慰 時(shí)間: 2025-3-28 01:18
On the Shape of Mathematical Argumentsies. However, because of the toxicity of myeloablative conditioning it had been limited to young patients in good medical condition. The use of less intensive nonablative regimens may provide a strategy that allows exploitation of the graft-versus-leukemia effect in older and debilitated patients.作者: HUSH 時(shí)間: 2025-3-28 05:07
On the Shape of Mathematical Argumentsve established a novel culture system in which the murine stromal cell line HESS-5 dramatically supports the rapid expansion of cryopreserved cord blood primitive progenitor cells (CB-PPC) in synergy with TPO/FL. Within 5 days of serum-free culture in this system, a 50- to 100-fold increase in CD34+作者: 越自我 時(shí)間: 2025-3-28 08:26 作者: AGOG 時(shí)間: 2025-3-28 11:49 作者: 使閉塞 時(shí)間: 2025-3-28 16:25
Gene Encoding Squamous Cell Carcinoma Antigen Recognized by Cytotoxic T Lymphocytesby the HLA-A26-restricted CTLs, and was able to induce in vitro the HLA-A26-restricted and SART-1.. tumor-specific CTLs from peripheral blood mononuclear cells (PBMCs) of cancer patients. On the other hand, the SART1 peptide at position 690–698 was recognized by the HLA-A24-restricted CTLs, and also作者: 人造 時(shí)間: 2025-3-28 20:13
Adoptive Immunotherapy of Human Diseases with Antigen-Specific T-Cell Clonespriately to sites of disease. It is anticipated that additional studies will define disease settings in which T-cell therapy can be beneficial and further elucidate the requirements for effective immunotherapy in humans.作者: Lime石灰 時(shí)間: 2025-3-28 23:06
Adoptive Transfer of Polyclonal, EBV-Specific Cytotoxic T-Cell Lines for the Prevention and Treatmenymphomas most commonly occur in patients who are severely immunosuppressed and hence do not use immune evasion strategies. We have shown that these tumors can be treated effectively with infusions of virus-specific CTLs. The tumors occurring in patients who are immunocompetent or only mildly immunos作者: BALE 時(shí)間: 2025-3-29 04:02 作者: PAGAN 時(shí)間: 2025-3-29 10:12
Immunotherapy of Melanoma Using Dendritic Cellsissions). Immune escape mechanisms were evident at various levels of antigen presentation, including defects in expression of proteasomal antigens, TAP deficiency, melanoma antigen loss variants, and absent expression of relevant HLA surface molecules. DC vaccination for induction of an antitumor re作者: SUE 時(shí)間: 2025-3-29 14:27
Immunotherapy of Melanoma Using T-Cell-Defined Antigensnical trials have been performed in the Surgery Branch of the National Cancer Institute, USA. The immunization with the gp100. peptide that was modified to have high HLA-A2-binding affinity, along with incomplete Freund’s adjuvant and interleukin-2, resulted in 42% response rate in patients with mel作者: 提煉 時(shí)間: 2025-3-29 18:38
Isolation and Characterization of CD34-Low/Negative Mouse Hematopoietic Stem Cells by dividing very slowly. Furthermore, analysis of aged mice revealed more than tenfold increase in absolute number of CD34.KSL cells. Those CD34.KSL cells in aged mice appeared to include HPP-CFC at an equivalent frequency with those in younger mice. These data support our previous notion that CD34作者: Electrolysis 時(shí)間: 2025-3-29 21:22
Ex Vivo Expansion of Human Hematopoietic Stem Cellsfold in serum-free culture by day 14. More than 100-fold expansion of total and multipotential progenitors was obtained from CD34.IL-6R. cells but not from CD34.IL-6R. cells in culture with sIL-6/IL6/SCF. Addition of thrombopoietin (TPO) to culture with sIL-6R/IL-6/SCF or sIL-6/IL-6/FL significantly作者: cardiopulmonary 時(shí)間: 2025-3-30 02:34 作者: 分開(kāi) 時(shí)間: 2025-3-30 06:17
Molecular Genetics of Acute Promyelocytic Leukemia: A Rationale for “Transcription Therapy” for Cancathogenesis allows the development of new therapeutic approaches. In particular, the recent elucidation of the molecular mechanisms underlying the pathogenesis of acute promyelocytic leukemia has allowed us to propose and exploit what we regard as a new concept for the treatment of cancer, which we 作者: CARK 時(shí)間: 2025-3-30 08:19
A Novel Acute Promyelocytic Leukemia Model: From Cell to Murine Systemlecular studies on blocking of leukemic cell differentiation and as a means to investigate the mechanisms of RA resistance. Moreover, this murine model system will be important for developing novel therapeutic strategies in RA-resistant APL.作者: slow-wave-sleep 時(shí)間: 2025-3-30 15:19 作者: interrogate 時(shí)間: 2025-3-30 19:07 作者: Vasodilation 時(shí)間: 2025-3-30 23:26
Ex Vivo Expansion of Hematopoietic Cells media containing 100 ng/ml each of rhSCF, rhG-SCF, and rhMGDF in 1-l teflon bags. After culture the cells were washed with 3 volumes of PBS to remove all media and growth factors and reinfused with doily administration of rhG-CSF. In both studies, unexpanded cells were given in addition to the expa作者: 猛擊 時(shí)間: 2025-3-31 02:07
Ex Vivo Expansion of Human Cord Blood Stem Cells and Genetic ManipulationIC was obtained. SRC and their multilineage differentiation were detected in NOD/SCID mice 7 weeks after injection of these cultured cells. This system is further applicable to retrovirus mediated gene transfer to CB-PPC. The transduction efficiency of CD34+ cells was more than 40% when they were in作者: 長(zhǎng)矛 時(shí)間: 2025-3-31 05:22
hematopoietic stem cell transplantation. Included in the third part is information on bone marrow registries from around the world..The book thus presents up-to-date information on biological and clinical aspects of treatment, with insight into the future of cell therapy.978-4-431-68508-1978-4-431-68506-7作者: 谷類 時(shí)間: 2025-3-31 11:47
On a proof by Arbib, Kfoury, and Moll,by the HLA-A26-restricted CTLs, and was able to induce in vitro the HLA-A26-restricted and SART-1.. tumor-specific CTLs from peripheral blood mononuclear cells (PBMCs) of cancer patients. On the other hand, the SART1 peptide at position 690–698 was recognized by the HLA-A24-restricted CTLs, and also作者: CLAIM 時(shí)間: 2025-3-31 16:32 作者: 本土 時(shí)間: 2025-3-31 17:44 作者: 有常識(shí) 時(shí)間: 2025-4-1 01:19
,Proving theorems with Euclid’s algorithm, antibodies that directly identify specific MHC-peptide complexes. We have used antibodies to show that dendritic cells efficiently present peptides from dying cells. Dendritic cells also express high levels of costimulatory molecules (e.g., CD40, CD86) for T-cell stimulation, and select chemokine r作者: Original 時(shí)間: 2025-4-1 03:52
,Proving theorems with Euclid’s algorithm,issions). Immune escape mechanisms were evident at various levels of antigen presentation, including defects in expression of proteasomal antigens, TAP deficiency, melanoma antigen loss variants, and absent expression of relevant HLA surface molecules. DC vaccination for induction of an antitumor re作者: crutch 時(shí)間: 2025-4-1 07:26
On a proof by Arbib, Kfoury, and Moll,nical trials have been performed in the Surgery Branch of the National Cancer Institute, USA. The immunization with the gp100. peptide that was modified to have high HLA-A2-binding affinity, along with incomplete Freund’s adjuvant and interleukin-2, resulted in 42% response rate in patients with mel
